NCT00886795View on ClinicalTrials.gov

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Urticaria

Interventions

DRUG

abatacept (Orencia ®)

4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.

Trial Locations (1)

21224

Johns Hopkins Arthritis Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Johns Hopkins University

OTHER